Humacyte, Inc.
HUMA
$1.26
-$0.05-3.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.59% | -50.81% | -149.55% | 13.72% | -574.89% |
| Total Depreciation and Amortization | -1.36% | -0.98% | -10.29% | -13.60% | -13.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -554.41% | 169.52% | 1,936.90% | -53.79% | 106.97% |
| Change in Net Operating Assets | -179.88% | -51.58% | 217.56% | -2,830.82% | 250.53% |
| Cash from Operations | -39.48% | -76.11% | 5.80% | -46.70% | -0.50% |
| Capital Expenditure | 58.00% | -89.45% | 62.06% | 66.06% | 77.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 58.00% | -89.45% | -111.34% | 66.06% | -102.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14.46% | -14.21% | 98.01% | -14.20% | -13.51% |
| Issuance of Common Stock | 19,726.88% | 400.00% | 728.42% | 36,368.91% | -17.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 454.20% | -101.59% | -- | -- |
| Cash from Financing | 15,325.67% | 211.13% | -107.76% | 15,453.30% | -58.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 224.70% | -61.19% | -46.61% | 273.53% | -39.97% |